| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GCA |
| Uniprot No | P28676 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-217aa |
| 氨基酸序列 | MAYPGYGGGFGNFSIQVPGMQMGQPVPETGPAILLDGYSGPAYSDTYSSAGDSVYTYFSAVAGQDGEVDAEELQRCLTQSGINGTYSPFSLETCRIMIAMLDRDHTGKMGFNAFKELWAALNAWKENFMTVDQDGSGTVEHHELRQAIGLMGYRLSPQTLTTIVKRYSKNGRIFFDDYVACCVKLRALTDFFRKRDHLQQGSANFIYDDFLQGTMAI |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于GCA(粒细胞相关抗原)重组蛋白的参考文献示例(注：GCA在不同领域可能有不同含义，此处假设为免疫学相关抗原研究)：
---
1. **标题**：*Expression and purification of recombinant granulocyte-specific antigen (GCA) for autoimmune disease studies*
**作者**：Smith J, et al.
**摘要**：研究报道了通过大肠杆菌系统高效表达GCA重组蛋白，优化纯化工艺，并验证其在抗中性粒细胞胞质抗体(ANCA)相关血管炎诊断中的潜在应用。
2. **标题**：*Structural characterization of recombinant GCA protein and its epitope mapping*
**作者**：Wang L, et al.
**摘要**：利用X射线晶体学解析了重组GCA蛋白的三维结构，通过肽阵列技术鉴定了其与自身抗体结合的关键抗原表位，为靶向治疗提供结构基础。
3. **标题**：*Recombinant GCA as a biomarker in rheumatoid arthritis: Clinical validation study*
**作者**：Garcia R, et al.
**摘要**：临床队列研究表明，血清中重组GCA蛋白的抗体水平与类风湿关节炎疾病活动度显著相关，提示其作为疾病监测生物标志物的潜力。
---
注：以上内容为模拟文献，实际研究中建议通过PubMed或Web of Science以“recombinant GCA protein”“granulocyte antigen recombinant”等关键词检索最新论文。若需具体领域(如病毒学GCA)，请补充说明以调整检索方向。
**Background of GCA Recombinant Protein**
GCA (Granzyme A) recombinant protein is a engineered form of the naturally occurring cytotoxic protease involved in immune responses. Granzyme A, primarily produced by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, plays a critical role in inducing apoptosis in target cells, such as virus-infected or cancerous cells, through DNA damage and caspase-independent pathways. Its recombinant version is synthesized using biotechnological platforms, such as *E. coli* or mammalian expression systems, to ensure high purity and scalability for research and therapeutic applications.
The development of GCA recombinant protein stems from the need to study its biological functions, including its dual role in promoting inflammation and immune regulation. Researchers utilize this protein to explore its interactions with substrates like histone H1 and its ability to activate pro-inflammatory cytokines, such as IL-6 and TNF-α. Additionally, recombinant GCA aids in elucidating its non-apoptotic roles, such as extracellular matrix remodeling and antimicrobial defense.
In therapeutic contexts, GCA recombinant protein is investigated for its potential in cancer immunotherapy, particularly in enhancing T-cell-mediated tumor clearance. Challenges remain in optimizing its stability and delivery *in vivo*, given its susceptibility to proteolytic degradation. Recent advances in protein engineering, such as site-specific mutagenesis or PEGylation, aim to improve its pharmacokinetics.
Overall, GCA recombinant protein serves as a vital tool for dissecting immune mechanisms and developing targeted therapies, bridging gaps between basic immunology and clinical translation. Ongoing studies focus on its synergistic effects with other granzymes and checkpoint inhibitors to amplify antitumor efficacy.
×
